Evolution of Management and Outcomes of Patients with Myocardial Injury During the COVID-19 Pandemic

[摘要] Cardiac involvement in coronavirus disease 2019 (COVID-19) has been established. This is manifested by troponin elevation and associated with worse patient prognosis. We evaluated whether patient outcomes improved as experience accumulated during the pandemic. We analyzed COVID-19-positive patients with myocardial injury (defined as troponin elevation) who presented to the MedStar Health system (11 hospitals in Washington, DC, and Maryland) during the Early Phase of the pandemic (March 1 - June 30, 2020) and compared their characteristics and outcomes to the COVID-19-positive patients with the presence of troponin elevation in the Later Phase of the pandemic (October 1, 2020 - January 31, 2021). The cohort included 788 COVID-19-positive admitted patients for whom troponin was elevated, 167 during the Early Phase and 621 during the Later Phase. Maximum troponin-I in the Early Phase was 13.46 +/- 34.72 ng/mL versus 11.21 +/- 20.57 ng/mL in the Later Phase (p = 0.553). In-hospital mortality was significantly higher in the Later Phase (50.3% vs. 24.6%; p<0.001), as were incidence of intensivecare-unit admission (77.8% vs. 46.1%; p<0.001) and need for mechanical ventilation (61.7% versus 28%; p<0.001). In addition, more Early Phase patients underwent coronary angiography (6% vs. 2.3%; p=0.013). Finally, 3% of Early Phase and 0.8% of Later Phase patients underwent percutaneous coronary intervention (p=0.025). In conclusion, treatment outcomes have significantly improved since the beginning of the pandemic in COVID-19-positive patients with troponin elevation. This may be attributed to awareness, severity of the disease, improvements in therapies, and provider experience. (C) 2021 Published by Elsevier Inc.

[发布日期] 2021-10-15